Proactive Investors - Run By Investors For Investors

Summit Therapeutics in a great position nearing the business end of its development

Glyn Edwards, chief executive of Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT), caught up with Proactive Investors following the news they'd entered into a revenue sharing agreement with the Wellcome Trust for their ridinilazole drug for the treatment of clostridium difficile infection (CDI).

The deal follows a translational award (TA) funding agreement with the Wellcome Trust in October 2012, which provided funds for the Phase 1 and II clinical trials of ridinilazole that have since been completed.

Phase III clinical trials are scheduled to begin in the first half of 2018, the company said in a statement on Monday.

 
Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use